The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone

Abstract

Overexpression of dickkopf (DKK)-1 in pagetic osteoblast cultures resulted in stimulation of osteoclast proliferation and inhibition of osteoblast growth. The aim of this study was to evaluate for the first time in Paget's disease of bone (PDB): 1) the serum levels of DKK1; 2) the association of DKK-1 with receptor activator of nuclear factor kappa B (RANKL) and osteoprotegerin (OPG); and 3) the effect of zoledronic acid (ZOL) on serum DKK-1, RANKL, and OPG. The study was conducted as a prospective open-label cohort study. Eleven patients with PDB (median age 60 years) were recruited. Twelve age- gender- and body mass index (BMI)-matched healthy individuals were used as controls at baseline. Blood samples were obtained before treatment (baseline) and after 3, 6, 12, and 18 months following ZOL infusion in patients with PDB. Patients with PDB had significantly higher RANKL (p=0.002), OPG (p=0.001), and bone markers (total alkaline phosphatase and C-terminal cross-linking telopeptide of type I collagen) compared with controls at baseline. There was no difference between groups in DKK-1 at baseline. Bone markers were both significantly decreased after therapy. Serum OPG, RANKL, RANKL:OPG ratio, and DKK-1 remained unaffected throughout the study. No correlations were found between OPG, RANKL, RANKL:OPG ratio, and DKK-1 at baseline nor between their changes during the study. Although both OPG and RANKL were increased in patients with PDB, ZOL had no effect on their serum levels. Serum DKK-1 was neither increased in patients with PDB nor related to OPG and RANKL, and was unaffected by ZOL.

Key words

dickkopf - nuclear factor kappa B - osteoprotegerin - Paget's disease - RANKL - zoledronic acid

References

• 1 Cundy T, Bolland M. Paget disease of bone.  Trends Endocrinol Metab. 2008;  19 246-253
• 2 Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone.  Lancet. 2008;  372 155-163
• 3 Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.  Osteoporos Int. 2008;  19 1109-1117
• 4 Selby PL. Guidelines for the diagnosis and management of Paget's disease: a UK perspective.  J Bone Miner Res. 2006;  21 ((Suppl 2)) 92-93
• 5 Xu J, Wu HF, Ang ES, Yip K, Woloszyn M, Zheng MH, Tan RX. NF-kappaB modulators in osteolytic bone diseases.  Cytokine Growth Factor Rev. 2009;  20 7-17
• 6 Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.  J Clin Endocrinol Metab. 2007;  92 4514-4521
• 7 Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De PV, Valleggi F, Nuti R. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.  Bone. 2007;  40 457-463
• 8 Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Munoz-Gomez J, Ballesta AM. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.  Arthritis Rheum. 2003;  48 824-828
• 9 Mossetti G, Rendina D, De FG, Viceconti R, Di DG, Cioffi M, Postiglione L, Nunziata V. Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.  Bone. 2005;  36 549-554
• 10 Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, Michigami T. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells.  J Cell Biochem. 2008;  104 304-317
• 11 Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling.  J Clin Invest. 2006;  116 1202-1209
• 12 Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF.  Mol Cancer. 2007;  6 71
• 13 Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Reid IR. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone.  J Bone Miner Res. 2007;  22 298-309
• 14 Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.  J Bone Miner Res. 2007;  22 142-148
• 15 Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.  N Engl J Med. 2005;  353 898-908
• 16 Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA. Comparison of three intravenous regimens of clodronate in Paget disease of bone.  J Bone Miner Res. 1996;  11 178-182
• 17 Kaiser M, Mieth M, Liebisch P, Oberlander R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.  Eur J Haematol. 2008;  80 490-494
• 18 Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P, Garnero P. Increased Dickkopf-1 expression in breast cancer bone metastases.  Br J Cancer. 2007;  97 964-970
• 19 Neale SD, Smith R, Wass JA, Athanasou NA. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.  Bone. 2000;  27 409-416
• 20 Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.  Biochem Biophys Res Commun. 2002;  291 680-686
• 21 Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).  J Bone Miner Res. 2004;  19 147-154
• 22 Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.  Horm Metab Res. 2008;  40 281-285
• 23 Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.  Endocr Rev. 2008;  29 155-192
• 24 Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.  J Bone Miner Metab. 2008;  26 635-641
• 25 Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.  Drugs. 2003;  63 417-437

Correspondence